AI Terminal
Assura PLC
Capital/Financing Update • Mar 3, 2025
4924_rns_2025-03-03_68baf538-59fd-48dd-b138-0d41c20bb862.html
Capital/Financing Update
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9556Y
Assura PLC
03 March 2025
3 March 2025
Assura plc ("Assura" or the "Company")
Assura achieves £200m disposal milestone
Assura plc, the UK's leading diversified healthcare REIT, is pleased to announce it has exchanged on the disposal of seven assets for a gross consideration of £64 million.
The latest disposals mean that since the start of the financial year, the Company has sold 30 assets for gross proceeds of £200 million at a weighted average net initial yield of 4.8%.
The net proceeds have been deployed in reducing the acquisition debt used to finance the £500 million private hospital portfolio acquired in August 2024 at 5.9% yield on cost.
The disposal announced today marks further progress in Assura's overall debt reduction plans and the Company's proforma net LTV will reduce to 47%.
The sale also reinforces that the quality of the Company's portfolio and the resilience of its underlying cash flows remain highly attractive to the investment market.
The disposal is immediately earnings enhancing as the cash receipts will be used to repay the revolving credit facility.
The seven assets disposed of today have been sold into Assura's £250 million joint venture. Assura retains a 20% equity interest in the joint venture resulting in net proceeds of £51 million. Following this transaction, the joint venture has gross assets of £172 million. Assura continues to act as property and asset manager to the joint venture, receiving management fees linked to the valuation of the portfolio.
Jonathan Murphy, CEO, said:
"Reaching this £200 million milestone in our disposal programme means we are on track to achieve our target of net debt to EBITDA below 9 times and LTV below 45% well ahead of the previously outlined timetable. This accelerated delivery and our ability to achieve sales is testament to our operational excellence and the quality and attractiveness of our property portfolio.
"The disposal programme was announced at the time of our transformational acquisition of high-quality private hospital assets in August 2024. The acquisition has positioned Assura as a leader in a structurally supported market, and has cemented our position as the UK's leading diversified healthcare REIT offering an attractive investment opportunity into favourable long-term trends."
- Ends -
For more information, please contact:
| Assura plc | Tel: 0161 515 2043 |
| David Purcell, Investor Relations Director | Email: [email protected] |
| FGS Global Gordon Simpson Grace Whelan |
Tel: 0207 251 3801 Email: [email protected] |
Notes to Editors
About Assura plc
Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.
A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices and has a secondary listing on the Johannesburg Stock Exchange. As at 30 September 2024, Assura's portfolio was valued at £3.2 billion and has a strong track record of growing financial returns and dividends for shareholders.
At Assura we BUILD for health and as the first FTSE 250 certified B Corp we are committed to keeping ESG at the heart of our strategy, creating Healthy Environments (E) and Healthy Communities (S) and maintaining a Healthy Business (G).
Further information is available at www.assuraplc.com
* EPRA is a registered trademark of the European Public Real Estate Association
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DISTPMFTMTATBPA